Clinical Trials Browser

OTHER × Rare Diseases × tremelimumab × Clear all

NCT02938793 2025-09-23

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Phase 2 Terminated

Neoplasms, Rare Diseases